

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10767870	
	Filing Date		2004-01-29	
	First Named Inventor	Mark Puder		
	Art Unit	1615		
	Examiner Name	Azpuru, Carlos A.		
	Attorney Docket Number	701039-053543-US		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0887076	EP	A	1998-12-30	SATURNUS AG		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10767870
	Filing Date		2004-01-29
	First Named Inventor	Mark Puder	
	Art Unit	1615	
	Examiner Name	Azpuru, Carlos A.	
	Attorney Docket Number	701039-053543-US	

1	ALDEMIR, M. et al., "The preventive effect of rofecoxib in postoperative intraperitoneal adhesions," Acta Chirurgica Belgica, Publications Acta Medica Belgica, Brussels, BE, 104(1):97-100 (2004).	<input type="checkbox"/>
2	GUVENAL, T. et al., "Prevention of postoperative adhesion formation in rat uterine horn model by nimesulide: a selective COX-2 inhibitor," Human Reproduction, 16(8):1732-1735 (2001).	<input type="checkbox"/>
3	LEGRAND, E.K. et al., "Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxae agents in a rabbit adhesion-prevention model," Journal of Investigative Surgery, Taylor and Francis, GB, 8(3):187-194 (1995).	<input type="checkbox"/>
4	RODGERS, K.E., "Nonsteroidal anti-inflammatory drugs (NSAIDS) in the treatment of postsurgical adhesion," Progress in Clinical and Biological Research, New York, NY, 358:119-129 (1990).	<input type="checkbox"/>
5	SIEGLER, A.M. et al., "Prevention of postoperative adhesions in rabbits with ibuprofen, a nonsteroidal anti-inflammatory agent," Fertility and Sterility, 34(1):46-49 (1980).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.